If primaquine or tafenoquine are indicated, quantitative glucose-6-phosphate dehydrogenase (G6PD) testing should be conducted before administration because of risk of hemolytic anemia and need for a modified regimen or alternative medication if G6PD deficiency is detected (9). This evidence concerns the gene G6PD and G6PD deficiency.